French biotech CellProthera welcomes three exceptional talents to its executive management team
17.11.2021 18:43:00 EET | Business Wire | Press release
CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs, has strengthened its executive management team to foster the development of its main clinical program and extend it to new therapeutic indications.
Ibon Garitaonandia is appointed Chief Scientific Officer (CSO). His extensive experience in drug discovery and in the development of novel stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years’ experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the first company to receive global regulatory approval to conduct a human pluripotent stem cell-based clinical trial for Parkinson’s disease.
Henk Streefkerk, MD PhD, takes the role of Chief Medical Officer (CMO). He brings decades of leadership in clinical research to boost the strategic development of the company and advance its pipeline of novel therapeutic solutions. After graduating from the University Medical Center Utrecht, Henk worked as Clinical Pharmacologist for Organon/Schering-Plough in the Netherlands. He then joined Actelion in Switzerland before taking the positions of Translational Medicine Expert and later Senior Brand Safety Leader with Novartis in Basel. After Novartis, he worked as Medical Director and Chief Medical Officer of a biotech specialized in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO). His solid history of helping companies and start-ups to scale up in their development journey is key for CellProthera as it enters its next stage of development. A lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and tax matters. He held leadership positions with Ernst & Young for more than 10 years, leading financial audits and due diligence transactions for a wide spectrum of industrial firms and as CFO, supporting the cash and financing management of listed companies in the energy and car industry.
“The arrival of these three talents - all experts in their field - in the executive management team is a great boost to our ambitious, multi-indications development program and position us ideally to accelerate our pathway to market.", stated Matthieu de Kalbermatten, Chairman of CellProthera. “The wealth of their international experience will be useful to shape and steer the company effectively during the next clinical and regulatory stages.”
CellProthera develops a medical innovation that enables a heart damaged by a heart attack to regenerate by injecting stem cells originated from the patient's own blood.
As such, each patient becomes his own source of medicine!
The stem cell product ProtheraCytes® is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future treatments that are often severe, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/fr/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006054/en/
Contact information
Press contact: Mediatiser – Antoine Monnier / amonnier@mediatiser.tv
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 08:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 08:00:00 EET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 04:14:00 EET | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ichthys interest shall be transferred, subject to the satisfaction of further conditions, to an existing joint venture participant in the Ichthys LNG project. The acquisition increases MidOcean’s equity exposure to a large-scale, long-life, integrated LNG project operated by Chevron, further strengthening its portfolio of high-quality producing assets. In par
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 17:34:00 EET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
Laserfiche Earns 5-Star Rating in the 2026 CRN® Partner Program Guide11.3.2026 16:00:00 EET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — has been honored by CRN®, a brand of The Channel Company, with a 5-Star Award in the 2026 CRN Partner Program Guide. This annual guide is an essential resource for partners seeking vendor partner programs that match their business goals and deliver high partner value. As organizations navigate growing pressure to increase productivity and respond to regulatory change, Laserfiche’s AI-powered document management solutions enable users to transform operations and achieve meaningful business results at scale. Partners that innovate with Laserfiche solutions have the opportunity to grow profits through the Laserfiche Partner Program, which equips them with the tools and resources needed to deliver customer success. Laserfiche’s partner ecosystem drives sustainable growth, delivers differentiated solutions and maximizes opportunities for both partners and their customers. Laserfiche provides comprehensive AI and clou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom